{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T15:54:51Z","timestamp":1668182091129},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.jash.2007.05.003","type":"journal-article","created":{"date-parts":[[2007,7,27]],"date-time":"2007-07-27T14:31:57Z","timestamp":1185546717000},"page":"286-294","source":"Crossref","is-referenced-by-count":7,"title":["Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results)"],"prefix":"10.1016","volume":"1","author":[{"given":"Subodh","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad M.","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Al-Omran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jash.2007.05.003_bib1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","article-title":"The cardiovascular continuum and renin-angiotensin-aldosterone system blockade","volume":"23","author":"Dzau","year":"2005","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.jash.2007.05.003_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"Strauss","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.05.003_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"McMurray","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2007.05.003_bib4","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.jash.2007.05.003_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2307\/2533160","article-title":"Matching using estimated propensity scores: relating theory to practice","volume":"52","author":"Rubin","year":"1996","journal-title":"Biometrics"},{"key":"10.1016\/j.jash.2007.05.003_bib6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2307\/2288398","article-title":"Reducing bias in observational studies using subclassification on the propensity score","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jash.2007.05.003_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1067\/mhj.2002.123839","article-title":"A multi-center study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario","volume":"144","author":"Austin","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2007.05.003_bib8","first-page":"351","article-title":"Towards improved coding of acute myocardial infarction in hospital discharge abstracts: a pilot project","volume":"13","author":"Cox","year":"1997","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jash.2007.05.003_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/aje\/154.9.854","article-title":"Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data","volume":"154","author":"Schneeweiss","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jash.2007.05.003_bib10","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.05.003_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.05.003_bib12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.05.003_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.05.003_bib14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA Study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.05.003_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.05.003_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","volume":"148","author":"Teo","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2007.05.003_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.0000096609.73772.C5","article-title":"Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease?","volume":"109","author":"Levy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.05.003_bib18","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1073\/pnas.92.23.10663","article-title":"The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer","volume":"92","author":"Nakajima","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jash.2007.05.003_bib19","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.05.003_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.05.003_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.05.003_bib22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.05.003_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.05.003_bib24","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.294.14.1794","article-title":"Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure","volume":"294","author":"Demers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2007.05.003_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1345\/aph.1E478","article-title":"Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations","volume":"39","author":"Epstein","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jash.2007.05.003_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2007.05.003_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.jhh.1001931","article-title":"Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension","volume":"20","author":"Cheung","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2007.05.003_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/bmj.38595.518542.3A","article-title":"Angiotensin receptor blockers and risk of myocardial infarction: systematic review","volume":"331","author":"McDonald","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2007.05.003_bib29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.hjh.0000194114.12228.16","article-title":"Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds","volume":"23","author":"Volpe","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.05.003_bib30","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/eurheartj\/ehi445","article-title":"Do angiotensin II receptor blockers increase the risk of myocardial infarction?","volume":"26","author":"Verdecchia","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jash.2007.05.003_bib31","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/eurheartj\/ehi574","article-title":"Is the jury out?","volume":"26","author":"Strauss","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jash.2007.05.003_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.jhh.1001873","article-title":"Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a Population-Based Study","volume":"19","author":"Bourgault","year":"2005","journal-title":"J Hum Hypertens"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171107001246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171107001246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T20:30:07Z","timestamp":1546720207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171107001246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S1933171107001246"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2007.05.003","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}